CAMBRIDGE, Mass., Sept. 20, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced that Science Signaling will publish the research article "Profiles of Basal and Stimulated Receptor Signaling Networks Predict Drug Response in Breast Cancer Lines" in its latest issue (Volume 6, ra84). The research article analyzes biochemical characteristics in a collection of breast cell cancer lines and identifies a group of hybrid biomarkers that effectively predicted the response of cells to targeted therapies in vitro. These findings are the result of collaboration between researchers at Merrimack Pharmaceuticals, Inc. and the laboratory of Peter Sorger, Ph.D., in the department of systems biology at Harvard Medical School.
An Analysis Of Cellular Networks To Predict Drug Response In Breast Cancer Lines Published In Science Signaling
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.